Interleukin 3 News and Research

RSS

Study addresses the role of macrophage activation syndrome in COVID-19

Scientists review macrophage activation syndrome — a feature of the cytokine storm that kills patients with severe cases of COVID-19, as well as possible treatments.

8 Sep 2020

Limited gut inflammation in COVID-19

A new study by researchers at the Icahn School of Medicine at Mount Sinai and published on the preprint server medRxiv in September 2020 shows that gut infection with this virus produces primarily mucosal immunity but also a limited inflammatory response.

8 Sep 2020

New consortium established to study the characteristics of blood cells

What's the risk of different human populations to develop a disease? To find out, a team led by Université de Montréal professor Guillaume Lettre created an international consortium to study the blood of hundreds of thousands of people worldwide.

4 Sep 2020

Study identifies subtypes and developmental process of novel immune T cells

There are memory cells that remember previously encountered pathogens and help to react quickly and strongly when exposed to them again.

2 Sep 2020

Key molecule can be used to assess prognosis of triple negative breast cancer

Hokkaido University scientists have shown that Interleukin-34 is a prognostic marker and drug target for Triple Negative Breast Cancer.

21 Aug 2020

A metabolic enzyme shows great potential as target for immunotherapies

The metabolic enzyme IL4I1 (Interleukin-4-Induced-1) promotes the spread of tumor cells and suppresses the immune system.

20 Aug 2020

Drug used in rheumatoid arthritis and cancer treatment improves survival in critically ill COVID-19 patients

Researchers at Hackensack Meridian Health, New Jersey's largest and most comprehensive health network, have utilized its statewide observational database of more than 5,000 hospitalized COVID-19 patients to show that a drug normally used in rheumatoid arthritis and cancer treatments, tocilizumab, improves hospital survival in critically-ill patients admitted to the intensive care unit (ICU).

20 Aug 2020

Researchers identify drug that improves survival in critically ill COVID-19 patients

19 Aug 2020

Cashew shell compound may help repair damaged nerves

In laboratory experiments, a chemical compound found in the shell of the cashew nut promotes the repair of myelin, a team from Vanderbilt University Medical Center reports today in the Proceedings of the National Academy of Sciences.

17 Aug 2020

Cardiovascular disease in COVID-19

The current COVID-19 pandemic is a primarily respiratory illness, manifesting with severe hypoxia and often progressing to acute respiratory distress syndrome (ARDS) and death. However, it is also known to be linked to a wide range of cardiovascular (CV) manifestations that are associated with a very poor prognosis.

13 Aug 2020

SARS-CoV-2 infection and transmission possible in North American deer mice

The current COVID-19 pandemic began as a zoonosis in China, at the end of 2019, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel betacoronavirus with significant similarity to an earlier virus of the same family.

11 Aug 2020

New type of immunotherapy shows promise for advanced skin cancer

A new type of immunotherapy for the skin cancer malignant melanoma shows promising results. Three severely ill patients are now long-term survivors.

7 Aug 2020

Interleukin-6 inhibitors appear to be a more effective treatment for COVID-19

New research from Boston Medical Center found that patients experiencing severe COVID-19 symptoms had improved outcomes when administered an Interleukin-6 (IL6ri) inhibitor, sarilumab or tocilizumab, given to mediate severe systemic inflammatory responses.

5 Aug 2020

Study examines glucocorticoid tapering in rheumatoid arthritis

Is the long-term use of glucocorticoids essential in people with chronic inflammatory diseases such as rheumatoid arthritis, or can early discontinuation prevent characteristic side effects?

31 Jul 2020

Study reveals manifold applications of cytokine transcriptional response modules in COVID-19

In a recent bioRxiv* study, UK researchers used interleukin modules to investigate the pathology of coronavirus disease (COVID-19).

27 Jul 2020

Study uncovers dual role for molecule involved in autoimmune eye disease

The inflammatory molecule interleukin-17A (IL-17A) triggers immune cells that in turn reduce IL-17A's pro-inflammatory activity, according to a study by National Eye Institute researchers.

23 Jul 2020

Type 1 interferon deficiency as a biomarker for detecting patients at risk of severe COVID-19

Approximately 5% of people with Covid-19 progress to a severe or critical form, including the development of severe pneumonia that progresses to acute respiratory distress syndrome.

17 Jul 2020

CBD may help reduce cytokine storm and excessive lung inflammation in COVID-19

Cannabidiol, or CBD, may help reduce the cytokine storm and excessive lung inflammation that is killing many patients with COVID-19, researchers say.

16 Jul 2020

Study identifies possible factors to predict severe toxicities in CAR T patients

Chimeric antigen receptor T-cell therapy (CAR T) has proved to be a valuable treatment option for patients with lymphoma who have failed other therapies. In clinical trials, the cellular immunotherapy was shown to provide durable remissions for nearly 40% of large B cell lymphoma patients.

15 Jul 2020

Anti-inflammatory medication helps fight dangerous immune response in COVID-19 patients

Most patients hospitalized with COVID-19 (coronavirus) pneumonia experienced improvement after receiving a Food and Drug Administration-approved drug normally given for rheumatoid arthritis, according to an observational study at Cedars-Sinai.

15 Jul 2020